Iftikhar Chaudhry, MD
Ophthalmology · Bensalem, PANPI 1700874740
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Alcon at 25.4% of the total. 2025 is the largest year on record at $1,913, 3.0 times the $639 reported in 2019.
Across 311 payments — averaging $26.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$996
- Regeneron Healthcare Solutions, Inc.$887
- Sun Pharmaceutical Industries Inc.$686
- Bausch & Lomb Americas Inc.$399
- Sight Sciences, Inc.$326
- plus $3K from 27 others
Across 53 payments — averaging $743.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$39K
What the payments were for
- Food & beverage$8,10199%
- Education$400%
- Gifts$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 75 | $2,079 |
| AbbVie(2 entities) | 38 | $996 |
| Regeneron Healthcare Solutions, Inc. | 7 | $887 |
| Sun Pharmaceutical Industries Inc. | 28 | $686 |
| Bausch & Lomb Americas Inc. | 20 | $399 |
| Sight Sciences, Inc. | 18 | $326 |
| Dompe US, Inc. | 10 | $283 |
| Biotissue Holdings Inc. | 12 | $276 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $275 |
| Glaukos Corporation | 6 | $227 |
| Tarsus Pharmaceuticals, Inc. | 6 | $189 |
| Aerie Pharmaceuticals, Inc. | 9 | $184 |
| Novartis | 13 | $180 |
| Harrow Eye, LLC | 9 | $162 |
| NEW World Medical,inc. | 5 | $160 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $126 |
| ANI Pharmaceuticals, Inc. | 6 | $115 |
| Abbott | 5 | $104 |
| Oyster Point Pharma, Inc. | 4 | $83 |
| Rayner Intraocular Lenses Limited | 4 | $78 |
| Amgen(2 entities) | 3 | $50 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| Ocular Therapeutix, Inc. | 2 | $34 |
| Beaver-visitec International, Inc. | 1 | $33 |
| Boston Scientific | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Eyepoint US, Inc. | 2 | $26 |
| Rxsight Inc | 1 | $23 |
| Dutch Ophthalmic, USA | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$509
- EYLEA HD$378
- WaveLight EX500 Excimer Laser$158
- LUMIGAN$126
- COMBIGAN$126
- DURYSTA$124
- CEQUA$122
- Hydrus Microstent$121
How this compares
$8,178 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 708 | $589,102 |
| Cyclosporine | 345 | $133,443 |
| LumiganBimatoprost | 254 | $122,274 |
| XiidraLifitegrast | 91 | $84,539 |
| RhopressaNetarsudil Mesylate | 158 | $82,139 |
| CombiganBrimonidine Tartrate/Timolol | 147 | $56,137 |
| Prednisolone Acetate | 1,514 | $52,740 |
| CequaCyclosporine | 49 | $31,096 |
| Travoprost | 175 | $31,047 |
| Latanoprost | 2,717 | $29,748 |
| Alphagan PBrimonidine Tartrate | 79 | $26,299 |
| Brimonidine Tartrate | 380 | $25,556 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,301 | $21,763 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 113 | $19,901 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 133 | $18,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $996 | $793,8121,188 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $399 | $99,546124 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $184 | $93,328175 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $686 | $31,09649 claims |
| AlconSimbrinza | $2,079 | $14,90860 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $126 | $6,16634 claims |
| NovartisTravatan Z | $180 | $3,04111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Bensalem
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.